#USA #New York #CAR T-Cell #Actinium #Iomab-ACT

Actinium Pharmaceuticals Announces Key Findings at ASH 2026

Actinium Pharmaceuticals, Inc., a leader in innovative targeted radiotherapies, has recently revealed three significant abstracts related to its ongoing clinical trials at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition. These studies emphasize the potential of Iomab-ACT, a cutting-edge CD45-targeted radioimmunotherapy, as a conditioning agent for CAR T-cell therapy and allogeneic stem cell transplantation, particularly in patients with severe sickle cell disease.

The abstracts presented include crucial data from various studies:
1. Iomab-ACT Prior to CD19-Directed CAR T-Cell Therapy: This study, conducted at the esteemed Memorial Sloan Kettering Cancer Center, highlights promising results regarding the efficacy of Iomab-ACT as a pre-conditioning treatment before utilizing CAR T-cell therapy, specifically focusing on enhancing CAR T-cell expansion, immune cell depletion, and managing treatment-related toxicities.
2. Investigational Use in Severe Sickle Cell Disease: Preliminary outcomes from this study suggest that the Iomab-ACT-based conditioning regimen might enable donor engraftment for sickle cell disease patients, minimizing the need for traditional chemotherapy approaches often employed in such settings.
3. Phase 1b/2 Trial Insights: This trial evaluates the safety and efficacy of Iomab-ACT followed by standard commercial CD19-directed CAR T-cell therapy, reinforcing the versatility of the treatment model and its significant clinical implications.

Actinium's Chairman and CEO, Sandesh Seth, expressed high hopes regarding these findings, stating that they represent a crucial advancement in the company's mission to incorporate Iomab-ACT into established cellular and gene therapy frameworks across various disease categories. Seth indicated, "Our research indicates that Iomab-ACT is uniquely positioned to not only improve cancer therapy outcomes but also extend its benefits to non-malignant diseases like severe sickle cell disease."

Presentation Highlights at ASH 2026

During the ASH event, multiple abstracts will be showcased, including:

• - First Preliminary Results of Anti-CD45 ¹³¹I-Radioimmunotherapy: This particular study will focus on the use of Iomab-ACT as a non-myeloablative conditioning methodology for siblings undergoing allogeneic stem cell transplantation aimed at patients suffering from severe sickle cell disease.
• - Low-Dose Iodine Approach: Results from this study indicated that the regiment employing low-dose ¹³¹I apamistamab prior to adoptive cellular therapy effectively enhances lymphodepletion rates while mitigating severe cytokine release syndrome (CRS) and neurologic toxicity.
• - Precise CD45-Directed Radioimmunotherapy: Here, Iomab-ACT's immune conditioning effectiveness will be examined prior to CD19-directed CAR T-cell therapy within the framework of lymphoid malignancies.

About Iomab-ACT

Iomab-ACT represents an ambitious step forward in the realm of precision medicine for cancer treatment. This investigational radio-conjugate combines an antibody targeting CD45 with iodine-131, designed to specifically prepare the immune environment in patients needing cellular therapies. By focusing on CD45-expressing hematopoietic and immune cells, Iomab-ACT aims to establish an optimal setting for subsequent therapies, which remain under rigorous clinical evaluation.

About Actinium Pharmaceuticals

Founded with a pioneering spirit, Actinium Pharmaceuticals focuses on transforming cancer treatments with innovative approaches in targeted radiotherapy. Their approach combines deep biological understanding, translational medicine principles, and advanced radiochemistry to create therapies that maximize efficacy while minimizing harmful side effects. The company's extensive pipeline includes distinctions in treating solid tumors, acute myeloid leukemia, and related areas, all built upon their commitment to improving oncological care.

In conclusion, the presented abstracts at ASH 2026 are a testament to Actinium's relentless pursuit of progress in the field of hematology and oncology, promising exciting advancements for patients suffering from cancer and hematological disorders.